News & Updates

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.

Minimally invasive surgery for nonendometrioid endometrial cancer performs comparably as open surgery, yielding similar survival outcomes, a recent study has found.

The risk of disease recurrence is increased among rectal cancer patients treated with dose-capped chemoradiotherapy (CRT), reveals a study. In addition, excessive toxicity has occurred among those dosed by actual body surface area (BSA) compared to patients in the dose-capped group.

The novel CRAFITY score—which takes into account C-reactive protein (CRP), alpha-foetoprotein (AFP), and immunotherapy—can be used to reliably assess survival and radiological response in hepatocellular carcinoma (HCC), a recent study has found. Future validation is needed before CRAFITY can be deployed to the clinics.

Negative upper endoscopy findings in patients with gastroesophageal reflux disease (GERD) indicate lower risk of developing upper gastrointestinal cancer, a new study has found.